Cargando…

Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA

BACKGROUND AND AIMS: With an increasing understanding of hepatitis B, the antiviral indications have been broadening gradually. To evaluate the effectiveness of tenofovir alafenamide (TAF) in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) and detectable hepatitis B vir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Wen-Kang, Shu, Yan-Yun, Chen, Yue, Ai, Yan, Yang, Xiao-Qian, Du, Fan, Ye, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845166/ https://www.ncbi.nlm.nih.gov/pubmed/35233379 http://dx.doi.org/10.14218/JCTH.2021.00131

Ejemplares similares

Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase
por: Zhou, Jiyuan, et al.
Publicado: (2017)

1236. Baseline liver stiffness and alanine transaminase predicts reduction in liver stiffness in people with chronic hepatitis B on tenofovir alafenamide
por: Tang, Lydia, et al.
Publicado: (2022)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
por: Lin, Hung-Yao, et al.
Publicado: (2022)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B
por: Li, Ming-Hui, et al.
Publicado: (2018)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
por: Chen, Ruochan, et al.
Publicado: (2021)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
por: Ogawa, Eiichi, et al.
Publicado: (2017)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B
por: Chen, Ruochan, et al.
Publicado: (2022)

Spleen thickness can predict significant liver pathology in patients with chronic hepatitis B with persistently normal alanine aminotransferase or minimally raised alanine aminotransferase: a retrospective study
por: Zhang, Junli, et al.
Publicado: (2018)

Expression Pattern of Serum Cytokines in Hepatitis B Virus Infected Patients with Persistently Normal Alanine Aminotransferase Levels
por: He, Dengming, et al.
Publicado: (2013)

One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study
por: Chen, Yi-Cheng, et al.
Publicado: (2022)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Alanine aminotransferase to aspartate aminotransferase ratio and hepatitis B virus on metabolic syndrome: a community-based study
por: Lin, Ming-Shyan, et al.
Publicado: (2022)

The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase
por: Diao, Yuting, et al.
Publicado: (2022)

Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase
por: Tan, You-Wen, et al.
Publicado: (2017)

Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase
por: Zeng, Da-Wu, et al.
Publicado: (2016)

Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
por: Byrne, Ruth, et al.
Publicado: (2018)

An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
por: Charlton, Michael R., et al.
Publicado: (2020)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Gamma-glutamyl Transpeptidase to Platelet Ratio Predicts Liver Injury in Hepatitis B e Antigen-negative Chronic Hepatitis B Patients With Normal Alanine Aminotransferase
por: Zhao, Xiang-An, et al.
Publicado: (2022)

HBeAg-negative Patients with Chronic Hepatitis B Virus Infection and Normal Alanine Aminotransferase: Wait or Treat?
por: Sheng, Qiuju, et al.
Publicado: (2022)

A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels
por: Li, Xiaoke, et al.
Publicado: (2021)

Evaluation of elevated alanine aminotransferase and hepatitis B virus DNA in healthy seronegative blood donors
por: Ali, Natasha, et al.
Publicado: (2012)

Lowering the threshold of alanine aminotransferase for enhanced identification of significant hepatic injury in chronic hepatitis B patients
por: Yu, Hong-Sheng, et al.
Publicado: (2023)

Age as a Predictor of Significant Fibrosis Features in HBeAg-Negative Chronic Hepatitis B Virus Infection with Persistently Normal Alanine Aminotransferase
por: Tan, Youwen, et al.
Publicado: (2015)

Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data
por: Lim, Young‐Suk, et al.
Publicado: (2022)

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial
por: Wang, Lu, et al.
Publicado: (2021)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Alterations of the Gut Microbiome in Chronic Hepatitis B Virus Infection Associated with Alanine Aminotransferase Level
por: Yun, Yeojun, et al.
Publicado: (2019)

A Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis B
por: Gong, Xianqiong, et al.
Publicado: (2015)

Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase
por: Wang, Dexin, et al.
Publicado: (2017)

A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels
por: Sinn, Dong Hyun, et al.
Publicado: (2017)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis
por: Ma, Xuefeng, et al.
Publicado: (2021)

A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels
por: Chen, Yanping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kfuuplucfoua11b5vako2b52dq